Every 8-K that Emeren Group Ltd American (SOL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SOL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SOL filings page.
Emeren Group Ltd reports that it has completed its previously announced merger with Shurya Vitra Ltd’s wholly owned subsidiary, making Emeren a wholly owned subsidiary of Shurya Vitra, which is affiliated with Himanshu H. Shah and Shah Capital Opportunity Fund LP.
At the effective time of the merger, each ordinary share and ADS was cancelled and converted into the right to receive the agreed per share and per ADS cash merger consideration, and holders ceased to have any other shareholder rights. The total cash consideration payable to equityholders at closing is approximately $65 million, funded from cash and other liquid assets on hand of Himanshu H. Shah.
Emeren has notified the NYSE, which has filed a Form 25 to remove its shares and ADSs from listing. Trading on the NYSE will cease before the market opens on December 15, 2025, and Emeren plans to file Form 15 to terminate registration and suspend its ongoing SEC reporting obligations.
Emeren Group Ltd reported the results of a shareholder meeting held on December 9, 2025, where investors voted on three proposals connected to a planned merger. The Merger Agreement Proposal was approved, with 92.8% of votes cast in favor, representing 255,113,810 votes for, 19,948,850 against, and 403,140 abstentions. Shareholders also approved the Advisory Compensation Proposal, which covers compensation arrangements related to the merger, with 91.1% support and vote totals of 250,033,000 for, 24,555,340 against, and 607,580 abstaining. Because both key proposals passed, the company did not need to consider the adjournment proposal, and no other business came before the meeting.
Emeren Group Ltd disclosed that its board, following the unanimous recommendation of a special committee of three independent directors, has authorized a Merger Agreement and will ask shareholders to approve the related transactions at an extraordinary general meeting to be held on October 21, 2025 at 10:00 a.m. Eastern Time in Raleigh, NC. The company filed a preliminary proxy statement and related Schedule 13E-3 and amendments with the SEC on September 2, 2025; the proxy is subject to completion or amendment. The filing attaches an amendment to the merger and rollover agreements and a press release as exhibits, and notes that the ADSs would no longer be listed or traded on the New York Stock Exchange if the Merger proceeds. Copies of the proxy and SEC filings are available at www.sec.gov and the company website.
Emeren Group (NYSE:SOL) disclosed that on 18 June 2025 it executed a definitive Agreement and Plan of Merger with Shurya Vitra Ltd. and its wholly owned subsidiary. Merger Sub will merge with Emeren, and Emeren will survive as a private company. Each ordinary share will be converted into $0.20 cash; each ADS, representing ten ordinary shares, will receive $2.00 cash, both without interest. The transaction was unanimously approved by an independent Special Committee and the full board.
Vested in-the-money options will be cashed out, while out-of-the-money or unvested options and RSUs will roll into substantially similar incentive awards of the surviving entity. Closing is subject to majority shareholder approval, required regulatory consents, accuracy of representations, and the absence of injunctions or material adverse effects.
The agreement contains a customary no-shop covenant with a fiduciary-out, mutual $4.5 million termination fees, and an outside date of 31 December 2025. Financing is backed by an equity commitment letter and limited guarantee from investor Himanshu H. Shah, intended to fund the entire merger consideration. Upon completion, Emeren’s ordinary shares and ADSs will be delisted from the NYSE and deregistered.